Open Access. Powered by Scholars. Published by Universities.®
Other Immunology and Infectious Disease Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Anatomy (1)
- Bacteriology (1)
- Biological Phenomena, Cell Phenomena, and Immunity (1)
- Cardiovascular System (1)
-
- Cells (1)
- Chemicals and Drugs (1)
- Equipment and Supplies (1)
- Immunopathology (1)
- Medical Cell Biology (1)
- Medical Microbiology (1)
- Medical Molecular Biology (1)
- Medical Pathology (1)
- Medical Sciences (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Microbiology (1)
- Other Analytical, Diagnostic and Therapeutic Techniques and Equipment (1)
- Pharmaceutical Preparations (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Respiratory System (1)
- Keyword
Articles 1 - 2 of 2
Full-Text Articles in Other Immunology and Infectious Disease
Pseudomonas Aeruginosa Exoenzyme Y Enzymatic Activity Inhibits Exoenzyme S-Induced Caspase Activation But Not Cytotoxicity In Pulmonary Microvascular Endothelial Cells, Connor Holm
Honors Theses
Pseudomonas aeruginosa (P. aeruginosa) is the most common cause of ventilator-associated pneumonia in intensive care unit patients. P. aeruginosa utilizes a type III secretion system that injects exoenzymes U, S, T, and/or Y into the host cell cytosol. A majority of clinically isolated P. aeruginosa strains express ExoY often in combination with ExoU and ExoT, or ExoS and ExoT. Host signaling mechanisms in response to intoxication with individual exoenzymes have been extensively studied, yet little is known about host cell response to co-intoxication. In this study, pulmonary microvascular endothelial cells (PMVECs) were infected with P. aeruginosa strains expressing different combinations …
Design And Synthesis Of Novel Analogs As Potential Antitubercular Agents, Peggy Mccluggage
Design And Synthesis Of Novel Analogs As Potential Antitubercular Agents, Peggy Mccluggage
Honors Theses
Tuberculosis (TB) is an infectious, airborne disease which primarily infects the lungs. One-third of the world’s population is currently estimated to be infected with Mycobacterium tuberculosis (Mtb), the causative agent for TB [1]. Current treatment for this disease requires at least six months of taking multiple antibiotics with undesirable side effects [2]. Difficulty in complying to this regimen as well as the prevalence of HIV/AIDS has led to antimicrobial resistance seen in Mtb. In order to combat the Multi-Drug Resistant and Extensively-Drug Resistant strains of the disease-causing bacteria, preventative care and novel antibiotics are urgently needed [3]. The purpose for …